Clinical Trials Logo

Ulcerative Colitis clinical trials

View clinical trials related to Ulcerative Colitis.

Filter by:

NCT ID: NCT03251118 Recruiting - Crohn's Disease Clinical Trials

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Start date: July 24, 2017
Phase: N/A
Study type: Observational [Patient Registry]

TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

NCT ID: NCT03239704 Not yet recruiting - Ulcerative Colitis Clinical Trials

Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Inflammatory Bowel Diseases (IBD) refers to a category of disorders, consisting of Crohn's Disease (CD) and Ulcerative Colitis (UC), where segments of the gastrointestinal tract become inflamed and ulcerated. Canada has among the highest incidence rates of IBD in the world - 16.3 and 12.3 per 100,000 for CD and UC respectively. In the absence of a cure, the current goal of treatment is to manage patients in a milder state of remission. However, maintaining (or even achieving) remission is dependent on timely access to specialist IBD care; which in light of rising incidence rates have proven to be challenging. Moreover, patients often experience flare-ups of their gastrointestinal symptoms, while awaiting access to specialist care. In recent years, there has been increased integration of telemedicine services in gastroenterology practice. This change has been driven by a desire among IBD patients to have more flexible follow-up care, where 'virtual' care is provided as an adjunct to in-person consultations. Within the context of IBD, telemedicine might be effective in delivering routine and timely follow-up care to high-risk patients. The purpose of this study to determine whether telemedicine-based follow-up care can effectively manage the gastrointestinal symptoms of high-risk IBD patients and reduce their need for preventive health care services.

NCT ID: NCT03237260 Recruiting - Ulcerative Colitis Clinical Trials

An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis

Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this research study is to determine whether starting the drug vedolizumab earlier than its FDA approved use can lead to better control of UC then using older drugs that we have historically used to treat UC. Vedolizumab is FDA-approved to be used after initial Corticosteroid treatments have failed or other UC treatments have failed. We will study if using vedolizumab as an early treatment for your UC will allow you to get off corticosteroids and prevent UC from worsening and requiring surgery. Vedolizumab is given intravenously initially every 2 weeks and then every 8 weeks.

NCT ID: NCT03232528 Recruiting - Ulcerative Colitis Clinical Trials

The Promotion Plan of Moxibustion on Ulcerate Colitis

Start date: November 1, 2016
Phase: N/A
Study type: Interventional

To evaluate the efficacy of Moxibustion in the treatment of Ulcerative Colitis, thus the scientific foundation for rational use of Moxibustion in clinical usage, in order to find admission of the Acupuncture and Moxibustion and even medicine field, accomplish popularization and application.

NCT ID: NCT03223012 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Ankylosing Spondylitis, in the Portuguese National Health Service

IMPROVE
Start date: July 31, 2017
Phase: N/A
Study type: Observational

This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.

NCT ID: NCT03218202 Not yet recruiting - Ulcerative Colitis Clinical Trials

Stricture Definition and Treatment (STRIDENT) Observational Study.

STRIDENT
Start date: September 2017
Phase: N/A
Study type: Observational

Two thirds of patients with Crohn's disease require intestinal surgery at some time in their life. Intestinal strictures, that is narrowing of the bowel due to inflammation and scarring, are the most common reason for surgery. Despite the high frequency, associated disability, and cost there are no are no treatment strategies that aim to improve the outcome of this disease complication. The STRIDENT (stricture definition and treatment) studies aim to determine biochemical and imaging features associated with the development of strictures and in related STRIDENT studies develop strategies for treatment.

NCT ID: NCT03209232 Not yet recruiting - Ulcerative Colitis Clinical Trials

Infliximab Accelerated Induction in Moderate to Severe Pediatric UC

INDUCE
Start date: September 2017
Phase: N/A
Study type: Interventional

Objectives: To examine the effect of accelerated infliximab induction in children with moderate to severe UC. Design: A multi-center, prospective, randomized, open label study. Setting: Pediatric gastroenterology centers. Participants: Children 6 year to 17 years (Overall, 84 patients) with moderate to severe UC who are corticosteroid dependent/resistant thus planned to receive infliximab induction. Intervention: Group 1 (intervention) will receive an accelerated induction at 0,1,3 weeks (5 mg/kg) and then at week 7,11,15. Group 2 (standard) will receive a per protocol induction at 0,2,6 weeks (5 mg/kg) and then at week 14. Drug levels will be obtained prior to each infusion in each group (up to week 20). Further maintenance will be planned according to drug levels at weeks 15 and 14, respectively. Follow-up will continue without further interventions till 52 weeks following induction. Main outcome measure: Clinical remission, on infliximab at week 20. Secondary outcome measures: 1. Colectomy free rates at week 20 and 52. 2. Clinical remission on infliximab at week 52. 3. Drug levels and anti-drug antibodies prior to last study infusion. 4. Anthropometric and laboratory measures including calprotectin at the end of induction, week 20 and week 52 5. Changes in fecal microbiome, virome and bile acids content. Sample size: In order to demonstrate 30% difference in clinical remission rate between groups is significant, we will need to study 36 children in each group to be able to reject the null hypothesis that the failure rates between the groups are equal with probability (power) of 80% and a type I error probability of 0.05.

NCT ID: NCT03201445 Recruiting - Ulcerative Colitis Clinical Trials

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis

Start date: July 11, 2017
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the testicular safety of filgotinib in adult males with moderately to severely active ulcerative colitis.

NCT ID: NCT03196427 Not yet recruiting - Crohn's Disease Clinical Trials

Long-term Safety With Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

Start date: November 10, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine vedolizumab IV safety profile, the effect of long-term treatment on time to major inflammatory bowel disease (IBD)-related events (hospitalizations, surgeries, and procedures), to examine the effect on health-related quality-of- life measurements and to determine the effect on patterns of growth and development in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD).

NCT ID: NCT03189888 Completed - Ulcerative Colitis Clinical Trials

Granulocyte-monocyte Apheresis in Ulcerative Colitis

Start date: January 2013
Phase: N/A
Study type: Interventional

BACKGROUND: Granulocyte-monocyte apheresis has been proposed for the treatment of ulcerative colitis, although is limited by costs and variability of results.